|
|
|
24.04.26 - 15:39
|
Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street (ZeroHedge)
|
|
|
Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street
Shares of Eli Lilly & Co. fell in New York premarket trading after new industry prescription data for the drugmaker's blockbuster obesity shot Zepbound and recently approved oral weight-loss pill Foundayo disappointed Wall Street analysts.
Foundayo generated 3,707 prescriptions in its second week, according to new prescription-tracking data from IQVIA cited by RBC Capital Markets analysts. That compares with 18,410 prescriptions for Novo's oral version of Wegovy during its second week after launch, suggesting Lilly's weight-loss drugs are falling behind in the GLP-1 race.
"While we believe comparisons early into launch should be considered immaterial, Foundayo's uptake this week is likely to be received negatively," RBC Capital Markets analyst Trung Huynh wrote in a note to clients earlier.
In a separate note citing the IQVIA data, Cantor analyst Carter Gould said, "We see slower TRx (total prescriptions) growth ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.04.26 - 22:18
|
MÄRKTE USA/Leichter - Softwareaktien stark unter Druck (Dow Jones)
|
|
|
Von Steffen Gosenheimer DOW JONES--Angesichts stockender Verhandlungen zwischen den USA und dem Iran ist am Donnerstag an der Wall Street nach den Vortagesgewinnen mit teils neuen Rekordständen wieder etwas Vorsicht eingezogen. Offiziell finden keine ......
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
